Safety study of BG-A3004 in healthy people and skin disease patients
Part of Skin clinical trials.
This study tests a new drug (BG-A3004) for safety in healthy volunteers and people with certain skin conditions like alopecia areata, cutaneous lichen planus, or vitiligo. It helps find out if the drug is safe and how the body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are either a healthy adult (18-55) or have one of three skin conditions: alopecia areata (patchy hair loss), cutaneous lichen planus (itchy, purple bumps), or nonsegmental vitiligo (white patches).
- You must be within a certain weight range (BMI 19-28 for healthy volunteers, 18-32 for patients).
- You cannot have had a serious infection needing hospital care or IV antibiotics in the past 6 months.
- You cannot have ever taken a JAK inhibitor (a type of medicine for immune conditions).
- No live vaccines in the past 28 days, and no history of tuberculosis, hepatitis B or C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental drug called PG-033 in healthy adults. It helps doctors find out if the drug is safe and how your body processes it at different dose levels.
This trial tests a single dose of a new medicine called PG-033 in healthy adults. It checks how the drug moves through the body and how food affects it, to find the safest starting dose for future studies.
This early-stage study tests a new ointment (YR001) on healthy volunteers to see how it is absorbed through the skin and how safe it is. It helps researchers understand how the ointment behaves in the body before it is tested in people with skin conditions.
This is an early-stage safety study of a new drug called IBI3013. The trial tests how safe the drug is and how your body processes it. It enrolls healthy volunteers first, then people with vitiligo (loss of skin color) or severe alopecia areata (patchy hair loss).
This trial tests a new medication called LAD603 for people with severe to very severe alopecia areata, a condition causing significant hair loss. It aims to see if the drug can help regrow hair.
This trial tests a new medicine (ABS-201) in healthy people to see if it is safe and works for hair loss. It involves multiple doses and compares results based on whether you have the common type of hair loss called androgenetic alopecia.
Hear when a new Skin Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.